Goldman Sachs’s Dogwood Therapeutics DWTX Stock Holding History

Goldman Sachs’s Portfolio DWTX Stock Details DWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,598	Closed	-$30.8K	–	7109
2026 Q1	$30.8K	Buy	+14,598	New	+$43K	﹤0.01%	6334

Other funds holding DWTX

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs's DWTX Position: Q2 2026 in Review

Goldman Sachs sold out of Dogwood Therapeutics (DWTX) in Q2 2026, closing a stake of 14,598 shares — an estimated $30.8K sold.

Goldman Sachs first reported a position in DWTX in Q1 2026 and held it in 1 quarter. The position peaked at $30.8K in Q1 2026. 15 funds tracked by Wall St. Rank hold DWTX as of Q2 2026.

Goldman Sachs reported no remaining Dogwood Therapeutics position as of Q2 2026 after selling out during the quarter.
Goldman Sachs sold 14,598 Dogwood Therapeutics shares in Q2 2026, an estimated $30.8K.
Goldman Sachs first reported a position in Dogwood Therapeutics in Q1 2026 and held it in 1 quarter.
Goldman Sachs's Dogwood Therapeutics position peaked at $30.8K in Q1 2026.
15 funds tracked by Wall St. Rank held Dogwood Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.